B lymphocytes cause post-stroke cognitive decline in mice. We therefore evaluated the association between autoantibodies and post-stroke cognitive decline in a prospectively collected human cohort. The mini-mental state exam (MMSE) was administered 30, 90, 180, and 365 days after stroke. Antibody titers to myelin basic protein (MBP), proteolipid protein, and several non-specific proteins were determined. Among 58 subjects with initial MMSE ≥ 20 and at least 2 MMSE examinations in the year after stroke, cognitive decline (MMSE decrease ≥2) occurred in 10 (17%) subjects. In multivariate analysis, MBP antibody titers were the only independent predictor of cognitive decline (OR = 9.02 [1.18, 68.90]; P = 0.03).
Patients who suffer stroke are at increased risk of cognitive decline and dementia. While some of the cognitive decline may be attributable to the stroke itself, the increased risk of cognitive decline is present for at least a decade after the index stroke (Desmond et al., 2002; Ivan et al., 2004) . Moreover, in a large study with cognition analyzed before and after stroke, the trajectories over time of different cognitive domains, particularly executive function, worsen after stroke (Levine et al., 2015) . The increased risk of cognitive worsening after stroke is thus not solely due to the acute loss of neurons related to the ischemic insult. The reason for this increased risk of cognitive decline in the years after stroke is not known.
In mice initially cognitively normal after stroke, we recently discovered that B lymphocytes infiltrate the brain and cause cognitive decline between 1 and 7 weeks after stroke (Doyle et al., 2015) . In human stroke survivors there are autoantibodies against brain antigens in blood (Bornstein et al., 2001; Dambinova et al., 2003; Kalev-Zylinska et al., 2013; Shibata et al., 2012) and B cells in the stroke lesions of those with dementia (Doyle et al., 2015) . In addition to the humoral responses, cellular responses against brain antigens also occur after stroke and both appear to predictive of functional outcome (Becker et al., 2011 , Becker et al., 2005 Shibata et al., 2012) . The contribution of these immune responses to cognitive outcomes, however, has not been evaluated.
In this study we followed cognitive function in the year after stroke using the mini-mental state examination (MMSE) and assessed antibodies to two central nervous system antigens, myelin basic protein (MBP) and proteolipid protein (PLP). These responses were compared to acquired autoantibodies to phospholipids and a vaccine-generated antibody against tetanus toxin (TT).
Materials and methods

Research subjects
We prospectively enrolled patients with ischemic stroke admitted to Harborview Medical Center from 9/2005 through 5/2009 whom were at least 18 years of age, could be enrolled within 72 h of symptom onset and were felt not likely to die from their stroke. Patients with ongoing therapy for malignancy, known HIV, Hepatitis B or C, brain tumor, anemia, and those taking immunomodulatory drugs were excluded. Blood was drawn at 3, 7, 30, 90, 180 and 365 days after stroke onset. A group of 40 subjects with no history of stroke was recruited as controls. Serum was stored at −80°until use. The study was approved by the Institutional Review Board and all subjects or their surrogates provided informed consent.
Clinical data
Demographic and clinical data were collected on all patients. Total infarct volume on initial diffusion weighted MRI was calculated by the ABC/2 method. The MMSE was administered at days 30, 90, 180 and 365. Only individuals with an initial MMSE score ≥20 were included. Journal of Neuroimmunology 295-296 (2016) 9-11 
